Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Oppenheimer

Gilead Sciences (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Oppenheimer in a research note issued to investors on Friday, Benzinga reports. They currently have a $105.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s target price points to a potential upside of 58.04% from the company’s current price.

Several other brokerages have also commented on GILD. Barclays decreased their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Mizuho decreased their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Cantor Fitzgerald decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Finally, Wells Fargo & Company reduced their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Trading Up 0.4 %

Shares of NASDAQ GILD traded up $0.28 during midday trading on Friday, hitting $66.44. The company’s stock had a trading volume of 2,148,483 shares, compared to its average volume of 7,237,620. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The business’s 50 day moving average is $72.10 and its two-hundred day moving average is $76.58. Gilead Sciences has a 12-month low of $65.90 and a 12-month high of $87.86. The firm has a market cap of $82.72 billion, a P/E ratio of 14.77, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the company earned $1.67 EPS. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences will post 6.55 EPS for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of GILD. Cetera Investment Advisers grew its holdings in shares of Gilead Sciences by 9.2% during the first quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after purchasing an additional 4,877 shares during the last quarter. Baird Financial Group Inc. boosted its stake in shares of Gilead Sciences by 3.9% during the first quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 16,643 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Gilead Sciences by 44.3% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 2,654 shares during the period. Donaldson Capital Management LLC grew its stake in Gilead Sciences by 12.5% in the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 641 shares during the period. Finally, Ergoteles LLC purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $2,304,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.